By Metro US
Posted on
(Reuters) – The UK drug regulator added an extremely rare nerve-damaging disorder, Guillain-Barré syndrome (GBS), as a very rare side effect of the AstraZeneca COVID-19 vaccine, updates on the agency’s website showed on Thursday.
Medicines and Healthcare products Regulatory Agency’s (MHRA) decision comes after the European medicines agency added GBS as a possible side-effect last month.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shinjini Ganguli)
Super Bowl champion Chiefs will open regular season at home against Ravens in AFC title game rematch
Charter flights for WNBA road games was an early Mother’s Day gift for players with children
Series Recap: Phillies Fall on Mother’s Day 7-6
PGA CHAMPIONSHIP ’24: Spieth gets another Grand Slam shot. Hardly anyone is talking about it
Boeser, Lindholm score 2 each as Canucks beat Oilers 4-3 to take 2-1 lead in West playoff series
The Latest | Cohen expected to take the stand as testimony in Trump hush money case enters 4th week
Democratic ad campaign tries to chip away at Trump support among rural swing voters in 3 key states
Person in custody following deadly stabbing in Manhattan on Mother’s Day
Eurovision banned the EU flag from the song contest. The EU is demanding to know why
The Latest | Israel marks memorial day, as hundreds of thousands flee Rafah assault
Violence is traumatizing Haitian kids. Now the country’s breaking a taboo on mental health services
Local governments struggle to distribute their share of billions from opioid settlements
First person to receive a genetically modified pig kidney transplant dies nearly 2 months later
Here’s what to know about conservatorships and how Brian Wilson’s case evolved
